专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07314631B1 Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV) 有权
标题翻译：使用重组减毒副流感病毒（PIV）作为载体，以防止由PIV和呼吸道合胞病毒（RSV）引起的疾病
公开(公告)号：US07314631B1
公开(公告)日：2008-01-01
申请号：US09458813
申请日：1999-12-10
申请人： Brian R. Murphy , Peter L. Collins , Anna P. Durbin , Mario H. Skiadopoulos , Tao Tao
发明人： Brian R. Murphy , Peter L. Collins , Anna P. Durbin , Mario H. Skiadopoulos , Tao Tao
IPC分类号： A61K39/155 , C12N7/00
CPC分类号： C12N15/86 , A61K39/12 , A61K39/155 , A61K39/165 , A61K2039/5254 , A61K2039/5256 , A61K2039/70 , C07K14/005 , C12N2760/18422 , C12N2760/18434 , C12N2760/18634 , C12N2760/18643 , C12N2760/18734
摘要： Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting and immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.
摘要翻译：提供了嵌合副流感病毒（PIV），其包含PIV载体基因组或反义基因组以及异源PIV或非PIV病原体的一个或多个抗原决定簇。这些嵌合病毒在人类和其他哺乳动物中是感染性和减毒性的，并且可用于针对一种或多种PIV或针对PIV和非PIV病原体的引发和免疫应答的疫苗制剂。还提供了分离的多核苷酸分子和掺入嵌合PIV基因组或抗原组的载体，其包括与编码抗原决定簇的一个或多个异源基因或基因组片段组合或整合的部分或完整PIV载体基因组或反义基因，的异源PIV或非PIV病原体。在本发明的优选方面，嵌合PIV掺入与来自异源PIV或非PIV病原体的一个或多个异源基因或基因组片段组合的部分或完整的人PIV载体基因组或反向异构体，其中所述嵌合病毒通过引入到嵌合基因组或反基因组中的各种突变和核苷酸修饰中的任一种减毒用作疫苗剂。

2. 发明授权

US07192593B2 Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens 有权
标题翻译：使用重组副流感病毒（PIVs）作为载体，以防止由PIV和其他人类病原体引起的感染和疾病
公开(公告)号：US07192593B2
公开(公告)日：2007-03-20
申请号：US09733692
申请日：2000-12-08
申请人： Brian R. Murphy , Peter L. Collins , Alexander C. Schmidt , Anna P. Durbin , Mario H. Skiadopoulos , Tao Tao
发明人： Brian R. Murphy , Peter L. Collins , Alexander C. Schmidt , Anna P. Durbin , Mario H. Skiadopoulos , Tao Tao
IPC分类号： A61K39/12 , A61K39/155
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/5256 , C12N15/86 , C12N2760/18422 , C12N2760/18622 , C12N2760/18643
摘要： Chimeric parainfluenza viruses (PIVs) incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric Ply genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen.
摘要翻译：嵌合型副流感病毒（PIV）掺入PIV载体基因组或反向原子团以及异源PIV或非PIV病原体的一个或多个抗原决定簇。这些嵌合病毒在人和其他哺乳动物中是感染性和减毒性的，并且可用于引发针对一种或多种PIV或针对PIV和非PIV病原体的免疫应答的疫苗制剂中。还提供了分离的多核苷酸分子和掺入嵌合Ply基因组或反向基团的载体，其包括与编码抗原决定簇的一个或多个异源基因或基因组片段组合或整合的部分或完整PIV载体基因组或反义基因，的异源PIV或非PIV病原体。

3. 发明授权

US07208161B1 Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences 失效
标题翻译：从克隆的核苷酸序列产生减毒副流感病毒疫苗
公开(公告)号：US07208161B1
公开(公告)日：2007-04-24
申请号：US09083793
申请日：1998-05-22
申请人： Brian R. Murphy , Peter L. Collins , Anna P. Durbin , Mario H. Skiadopoulos , Tao Tao
发明人： Brian R. Murphy , Peter L. Collins , Anna P. Durbin , Mario H. Skiadopoulos , Tao Tao
IPC分类号： A61K39/155 , C12N7/00
CPC分类号： C07K16/1027 , A61K39/00 , A61K2039/5254 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2760/18622 , C12N2760/18643 , C12N2760/18661
摘要： Isolated polynucleotide molecules provide recombinant PIV genomes and antigenomes for production of recombinant PIV vaccines. The recombinant genome or antigenome can be expressed with a nucleoprotein (N), phosphoprotein (P), and a large (L) polymerase protein to produce isolated infectious PIV particles. The recombinant PIV genome and antigenome can be modified to produce desired changes, for example to incorporate attenuating mutations from biologically derived PIV mutants or to create chimeric PIV clones, to generate attenuated, immunogenic viruses for vaccine use.
摘要翻译：分离的多核苷酸分子提供用于重组PIV疫苗生产的重组PIV基因组和抗原单体。可以用核蛋白（N），磷酸化蛋白（P）和大的（L）聚合酶蛋白来表达重组基因组或反基因组以产生分离的感染性PIV颗粒。可以修饰重组PIV基因组和反义基因组以产生所需的变化，例如从生物衍生的PIV突变体引入减毒突变或产生嵌合PIV克隆，以产生用于疫苗使用的减毒的免疫原性病毒。

4. 发明授权

US07632508B2 Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines 有权
标题翻译：减毒的人 - 牛嵌合副流感病毒（PIV）疫苗
公开(公告)号：US07632508B2
公开(公告)日：2009-12-15
申请号：US11324284
申请日：2006-01-04
申请人： Alexander C. Schmidt , Mario H. Skiadopoulos , Peter L. Collins , Brian R. Murphy , Jane E. Bailly , Anna P. Durbin
发明人： Alexander C. Schmidt , Mario H. Skiadopoulos , Peter L. Collins , Brian R. Murphy , Jane E. Bailly , Anna P. Durbin
IPC分类号： A61K39/12 , A61K39/155
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/543 , A61K2039/544 , C12N2760/18634 , C12N2760/18661
摘要： Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an immune response to PIV or other pathogens. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different pathogen, including different PIV virus to form the human-bovine chimeric PIV genome or antigenome.
摘要翻译：嵌合人 - 牛副流感病毒（PIV）在人类和其他哺乳动物中是感染性和减毒性的，并且在疫苗制剂中单独使用或组合用于引发对PIV或其它病原体的免疫应答。还提供了分离的多核苷酸分子和掺入嵌合PIV基因组或抗原组的载体，其包括部分或完整的人或牛PIV“背景”基因组或反基因组，其与一个或多个异源基因或基因组片段组合或整合，不同的PIV。本发明的嵌合人牛PIV包括部分或完整的“背景”PIV基因组或反义基因组，其衍生自或构图在人或牛PIV病毒与一个或多个异源基因或不同基因组的基因组片段组合病原体，包括不同的PIV病毒，以形成人 - 牛嵌合PIV基因组或抗原组。

5. 发明申请

US20090081728A1 PRODUCTION OF ATTENUATED NEGATIVE STRANDED RNA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES 审中-公开
标题翻译：从克隆核苷酸序列中产生衰减的病毒RNA病毒疫苗
公开(公告)号：US20090081728A1
公开(公告)日：2009-03-26
申请号：US12136765
申请日：2008-06-10
申请人： Brian R. Murphy , Peter L. Collins , Anna P. Durbin , Mario H. Skiadopoulos
发明人： Brian R. Murphy , Peter L. Collins , Anna P. Durbin , Mario H. Skiadopoulos
IPC分类号： C12P21/00 , C12N7/01 , C12N15/44 , C12N15/63
CPC分类号： A61K39/155 , A61K39/12 , A61K2039/5254 , A61K2039/543 , A61K2039/544 , C12N7/00 , C12N2760/18534 , C12N2760/18561 , C12N2760/18634
摘要： Attenuated, recombinant negative stranded RNA viruses suitable for vaccine use are produced from one or more isolated polynucleotide molecules encoding the virus. A recombinant genome or antigenome of the subject virus is modified to encode a mutation within a recombinant protein of the virus at one or more amino acid positions(s) corresponding to a site of an attenuating mutation in a heretologous, mutant negative stranded RNA virus. A similar attenuating mutation as identified in the heterologous negative stranded RNA virus is thus incorporated at a corresponding site within the recombinant virus to confer an attenuated phenotype on the recombinant virus. The attenuating mutation incorporated in the recombinant virus may be identical or conservative in relation to the attenuating mutation identified in the heterologous, mutant virus. By the transfer of mutations into recombinant negative stranded RNA viruses in this matter, candidate vaccine viruses are engineered to elicit a desired immune response against a subject virus in a host susceptible to infection thereby.
摘要翻译：减毒，从编码病毒的一个或多个分离的多核苷酸分子产生适合疫苗使用的重组负链RNA病毒。修饰受试病毒的重组基因组或反基因组，以在对应于本体异质突变体负链RNA病毒中的减毒突变位点的一个或多个氨基酸位置上编码病毒重组蛋白内的突变。因此，在异源负链RNA病毒中鉴定的类似的减毒突变被并入重组病毒中的相应位点，以在重组病毒上赋予减毒表型。结合在重组病毒中的减毒突变可以与异源突变病毒中鉴定的减毒突变相同或保守。通过将突变转移到重组负链RNA病毒中，候选疫苗病毒被工程化以在由此感染的宿主中引发针对受试者病毒的所需免疫应答。

6. 发明申请

US20120064569A9 PRODUCTION OF ATTENUATED NEGATIVE STRANDED RNA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES 审中-公开
标题翻译：从克隆核苷酸序列中产生衰减的病毒RNA病毒疫苗
公开(公告)号：US20120064569A9
公开(公告)日：2012-03-15
申请号：US12136765
申请日：2008-06-10
申请人： Brian R. Murphy , Peter L. Collins , Anna P. Durbin , Mario H. Skiadopoulos
发明人： Brian R. Murphy , Peter L. Collins , Anna P. Durbin , Mario H. Skiadopoulos
IPC分类号： C12P21/00 , C12N15/63 , C12N7/01 , C12N15/44
CPC分类号： A61K39/155 , A61K39/12 , A61K2039/5254 , A61K2039/543 , A61K2039/544 , C12N7/00 , C12N2760/18534 , C12N2760/18561 , C12N2760/18634
摘要： Attenuated, recombinant negative stranded RNA viruses suitable for vaccine use are produced from one or more isolated polynucleotide molecules encoding the virus. A recombinant genome or antigenome of the subject virus is modified to encode a mutation within a recombinant protein of the virus at one or more amino acid positions(s) corresponding to a site of an attenuating mutation in a heretologous, mutant negative stranded RNA virus. A similar attenuating mutation as identified in the heterologous negative stranded RNA virus is thus incorporated at a corresponding site within the recombinant virus to confer an attenuated phenotype on the recombinant virus. The attenuating mutation incorporated in the recombinant virus may be identical or conservative in relation to the attenuating mutation identified in the heterologous, mutant virus. By the transfer of mutations into recombinant negative stranded RNA viruses in this matter, candidate vaccine viruses are engineered to elicit a desired immune response against a subject virus in a host susceptible to infection thereby.
摘要翻译：减毒，从编码病毒的一个或多个分离的多核苷酸分子产生适合疫苗使用的重组负链RNA病毒。修饰受试病毒的重组基因组或反基因组，以在对应于本体异质突变体负链RNA病毒中的减毒突变位点的一个或多个氨基酸位置上编码病毒重组蛋白内的突变。因此，在异源负链RNA病毒中鉴定的类似的减毒突变被并入重组病毒中的相应位点，以在重组病毒上赋予减毒表型。结合在重组病毒中的减毒突变可以与异源突变病毒中鉴定的减毒突变相同或保守。通过将突变转移到重组负链RNA病毒中，候选疫苗病毒被工程化以在由此感染的宿主中引发针对受试者病毒的所需免疫应答。

7. 发明授权

US07201907B1 Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines 有权
标题翻译：减毒的人 - 牛嵌合副流感病毒（PIV）疫苗
公开(公告)号：US07201907B1
公开(公告)日：2007-04-10
申请号：US09586479
申请日：2000-06-01
申请人： Alexander C. Schmidt , Mario H. Skiadopoulos , Peter L. Collins , Brian R. Murphy , Jane E. Bailly , Anna P. Durbin
发明人： Alexander C. Schmidt , Mario H. Skiadopoulos , Peter L. Collins , Brian R. Murphy , Jane E. Bailly , Anna P. Durbin
IPC分类号： A61K39/12 , A61K39/155
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , A61K2039/543 , C12N2760/18634 , C12N2760/18643 , C12N2760/18645 , C12N2760/18661 , C12N2810/6072
摘要： Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response or as vectors for introducing heterologous genes into a host. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.
摘要翻译：嵌合人 - 牛副流感病毒（PIV）在人类和其他哺乳动物中具有感染性和减毒性，并且在疫苗制剂中单独使用或组合用于引发抗PIV免疫应答或作为将异源基因导入宿主的载体。还提供了分离的多核苷酸分子和掺入嵌合PIV基因组或抗原组的载体，其包括部分或完整的人或牛PIV“背景”基因组或反基因组，其与一个或多个异源基因或基因组片段组合或整合，不同的PIV。本发明的嵌合人牛PIV包括部分或完整的“背景”PIV基因组或反义基因组，其衍生自或构图在人或牛PIV病毒与一个或多个异源基因或不同基因组的基因组片段组合 PIV病毒形成人 - 牛嵌合PIV基因组或抗原组。

8. 发明授权

US07250171B1 Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein 有权
标题翻译：构建和使用表达嵌合糖蛋白的重组副流感病毒
公开(公告)号：US07250171B1
公开(公告)日：2007-07-31
申请号：US09459062
申请日：1999-12-10
申请人： Tao Tao , Mario H. Skiadopoulos , Peter L. Collins , Brian R. Murphy
发明人： Tao Tao , Mario H. Skiadopoulos , Peter L. Collins , Brian R. Murphy
IPC分类号： A61K31/155 , C12N15/00
CPC分类号： C12N15/86 , A61K2039/5256 , C07K2319/00 , C12N2760/18643
摘要： Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic domains, fragments, or epitopes of a second, antigenically distinct HPIV. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, and, optionally against respiratory syncytial virus (RSV). Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a HPIV vector genome or antigenome combined or integrated with one or more heterologous genome segment(s) encoding one or more antigenic determinant(s) of a heterologous PIV to encode a chimeric glycoprotein. In preferred aspects of the invention, the chimeric virus is attenuated for use as a vaccine agent by additional mutations or nucleotide modifications introduced into the chimeric genome or antigenome.
摘要翻译：提供了嵌合副流感病毒（PIV），其包含PIV载体基因组或经修饰的反义基因组，以编码掺入一个或多个异源抗原结构域，片段或第二抗原性不同HPIV表位的嵌合糖蛋白。这些嵌合病毒在人和其他哺乳动物中是感染性和减毒性的，并且可用于引发针对一种或多种PIV的免疫应答的疫苗制剂，以及任选地抗呼吸道合胞病毒（RSV）。还提供了分离的多核苷酸分子和掺入嵌合PIV基因组或反基因组的载体，其包括与编码异源PIV的一个或多个抗原决定簇的一个或多个异源基因组片段组合或整合的HPIV载体基因组或抗原子集，编码嵌合糖蛋白。在本发明的优选方面，嵌合病毒通过引入到嵌合基因组或反基因组中的附加突变或核苷酸修饰来减毒用作疫苗剂。

9. 发明授权

US07919301B2 Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from CDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens 有权
标题翻译：从CDNA回收重组人副流感病毒2型（HPIV2），并在免疫原性组合物中使用重组HPIV2，并作为载体引发针对PIV和其他人类病原体的免疫应答
公开(公告)号：US07919301B2
公开(公告)日：2011-04-05
申请号：US11864120
申请日：2007-09-28
申请人： Mario H. Skiadopoulos , Brian R. Murphy , Peter L. Collins
发明人： Mario H. Skiadopoulos , Brian R. Murphy , Peter L. Collins
IPC分类号： C12N7/01 , C12N15/63 , C07H21/00
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , C12N7/00 , C12N2760/18334 , C12N2760/18634 , C12N2760/18643 , C12N2760/18722 , C12N2760/18734 , C12N2760/18743 , C12N2760/18762
摘要： Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.
摘要翻译：提供重组人副流感病毒2型（HPIV2）病毒和相关的免疫原性组合物和方法。根据本发明提供的包含HPIV2嵌合和嵌合载体病毒的重组HPIV2病毒在许可哺乳动物受试者，包括人中是感染性和减毒的，并且可用于免疫原性组合物中，用于引发针对一种或多种PIV的免疫应答更多的非PIV病原体，或针对PIV和非PIV病原体。还提供了分离的多核苷酸分子和掺入重组HPIV2基因组或抗原组的载体。

10. 发明授权

US07820181B2 Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens 有权
标题翻译：从cDNA中回收重组人副流感病毒2型（HPIV2），并在免疫原性组合物中使用重组HPIV2，并作为载体诱导针对PIV和其他人类病原体的免疫应答
公开(公告)号：US07820181B2
公开(公告)日：2010-10-26
申请号：US10667141
申请日：2003-09-18
申请人： Mario H. Skiadopoulos , Brian R. Murphy , Peter L. Collins
发明人： Mario H. Skiadopoulos , Brian R. Murphy , Peter L. Collins
IPC分类号： A61K39/155
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , C12N7/00 , C12N2760/18334 , C12N2760/18634 , C12N2760/18643 , C12N2760/18722 , C12N2760/18734 , C12N2760/18743 , C12N2760/18762
摘要： Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.
摘要翻译：提供重组人副流感病毒2型（HPIV2）病毒和相关的免疫原性组合物和方法。根据本发明提供的包含HPIV2嵌合和嵌合载体病毒的重组HPIV2病毒在许可哺乳动物受试者，包括人中是感染性和减毒的，并且可用于免疫原性组合物，用于引发针对一种或多种PIV的免疫应答更多的非PIV病原体，或针对PIV和非PIV病原体。还提供了分离的多核苷酸分子和掺入重组HPIV2基因组或抗原组的载体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式